Related Experiment Video
Updated: Feb 26, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Targeting BCL-2-like Proteins to Kill Cancer Cells
Suzanne Cory1, Andrew W Roberts2, Peter M Colman1
1The Walter and Eliza Hall Institute of Medical Research, Victoria 3052, Australia; Department of Medical Biology, University of Melbourne, Victoria 3052, Australia.
BH3 mimetics are a new class of cancer drugs targeting the B cell lymphoma (BCL)-2 family to restore apoptosis. Venetoclax (ABT-199) shows promise, with emerging drugs targeting MCL-1 for broader cancer therapy.
Area of Science:
- Molecular Biology
- Oncology
- Drug Discovery
Background:
- Mutations affecting apoptosis are key in cancer development and treatment resistance.
- The B cell lymphoma (BCL)-2 protein family regulates apoptosis, making its members targets for cancer therapy.
- BH3-only proteins are natural antagonists of pro-survival BCL-2 family members.
Purpose of the Study:
- To review the discovery and function of the BCL-2 family in cancer.
- To outline the development of BH3 mimetic drugs.
- To discuss the therapeutic potential of BH3 mimetics in cancer treatment.
Main Methods:
- Review of scientific literature on BCL-2 family, apoptosis, and BH3 mimetics.
- Analysis of clinical trial data for venetoclax (ABT-199).
- Preclinical study evaluation of emerging BH3 mimetics.
Main Results:
- Venetoclax (ABT-199), a BCL-2 specific BH3 mimetic, is licensed for chronic lymphocytic leukemia.
- Ongoing trials investigate venetoclax for other cancers.
- Emerging BH3 mimetics targeting MCL-1 show preclinical promise for various cancer types.
Conclusions:
- BH3 mimetics represent a promising new class of anti-cancer drugs.
- Targeting BCL-2 family proteins offers a viable strategy to restore apoptosis in cancer cells.
- BH3 mimetics are poised to become significant therapeutic agents in oncology.
More Related Videos
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Intrinsic Apoptotic Pathway
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Treatment Resistant Cancers